Smith & Nephew plc: 2012 Annual Report (Form 20-F) Summary
Business Context and Reporting Period
Company: Smith & Nephew plc
Reporting Period: Fiscal year ended December 31, 2012
Business Overview: A global medical technology business operating in two primary divisions: Advanced Surgical Devices (ASD) and Advanced Wound Management (AWM). The company holds leadership positions in orthopaedic reconstruction, sports medicine, trauma, and advanced wound care.
Accounting Basis: International Financial Reporting Standards (IFRS) as issued by the IASB and adopted by the EU.
Key Financial Metrics
| Metric | 2012 Value | 2011 Value | Change |
|---|---|---|---|
| Revenue | $4,137 million | $4,270 million | -3% (Reported) +2% (Underlying) |
| Trading Profit | $965 million | $961 million | +6% (Underlying) |
| Trading Profit Margin | 23.3% | 22.5% | +80 bps |
| Operating Profit | $846 million | $862 million | -2% |
| Attributable Profit | $729 million | $582 million | +25% |
| Adjusted Attributable Profit | $679 million | $664 million | +2% |
| Basic EPS | 81.3 cents | 65.3 cents | +25% |
| Adjusted EPS (EPSA) | 75.7 cents | 74.5 cents | +2% |
| Cash Generated from Operations | $1,184 million | $1,135 million | +4% |
| Trading Cash Flow | $999 million | $838 million | +19% |
| Net Debt | $288 million | $138 million | Increased |
| Dividend per Share | 26.10 cents | 17.40 cents | +50% |
Material Changes vs. Prior Period
- Revenue Decline: Reported revenue decreased 3% primarily due to the disposal of the Clinical Therapies business (Bioventus) in May 2012 (-3% impact) and unfavorable currency translation (-2% impact). Underlying revenue grew 2%.
- Profitability: Trading profit increased 6% underlying, driven by efficiency savings and margin improvements. Operating profit decreased slightly due to restructuring costs and amortization, but Attributable Profit rose 25% due to a $251 million pre-tax profit on the disposal of the Clinical Therapies business.
- Acquisitions: Completed the acquisition of Healthpoint Biotherapeutics in December 2012 for $782 million in cash, significantly expanding the Advanced Wound Management portfolio in bioactives. This acquisition increased long-term borrowings.
- Dividend Policy: The Board announced a progressive dividend policy, increasing the interim dividend by 50% and proposing a final dividend up 50% from the prior year.
Guidance, Outlook, and Risks
- 2013 Outlook: Management expects market conditions to remain broadly similar to 2012. Advanced Wound Management is expected to grow above the market rate. Orthopaedic Reconstruction is expected to grow more slowly than the market due to product cycles and metal-on-metal headwinds, though performance is expected to improve throughout the year.
- Margin Guidance: Trading profit margin for 2013 is expected to be below the 23.3% achieved in 2012. This is due to the initial dilutive impact of the Healthpoint acquisition and the introduction of the US Medical Device excise tax.
- Strategic Priorities: Continued focus on investing in higher-growth products and geographies (Emerging Markets), simplifying the operating model to drive efficiency, and supplementing organic growth with acquisitions.
- Key Risks:
- Regulatory & Pricing: Dependence on government reimbursement and pricing pressures in established markets; potential impact of US medical device excise tax.
- Currency: Exposure to fluctuations between the US Dollar, Sterling, Swiss Franc, and selling currencies (Euro, Yen, AUD).
- Product Liability: Ongoing litigation regarding macrotextured knee components and metal-on-metal hip implants.
- Compliance: Ongoing monitoring of compliance programs following the FCPA settlement with the SEC and DOJ.
Investor Verification Checklist
- Healthpoint Integration: Verify the integration progress and revenue contribution of the Healthpoint Biotherapeutics acquisition in 2013 reports.
- Margin Trajectory: Monitor the impact of the US Medical Device excise tax and Healthpoint integration on the trading profit margin in 2013 to confirm if it remains below 23.3% as guided.
- Emerging Markets Growth: Track revenue growth in Emerging Markets (China, India, Brazil, Russia) to ensure it continues to outpace Established Markets.
- Legal Provisions: Review updates on the macrotextured knee component litigation and metal-on-metal hip implant claims to assess potential changes to provisions.
- Currency Hedging: Assess the effectiveness of hedging strategies given the volatility in the Euro and Sterling against the US Dollar.